Check-in time. Alphabetical order seems really easy to decipher until you actually have to find your name.
Singer’s panel-mates were Neon Therapeutics co-founder Nir Hacohen (left) and interim CEO Cary Pfeffer (right), who seem to have found something of critical importance on Hacohen’s fleece.
Here's a packed-house view of Biogen chief medical officer Al Sandrock giving an overview of Biogen’s approach to treating neurological diseases.
RA Capital founder and managing director Peter Kolchinsky going through the “chess” game his firm uses to get a broad look at the landscape of disease treatments in development.
PureTech CEO Daphne Zohar tweeting out some of the action before participating in a panel on neuroscience.
On that panel, Zohar, Biogen’s Sandrock (left), Forum Pharmaceuticals CEO Deborah Dunsire, and SR One president Jens Eckstein (right) discussed some of the challenges developing therapies for neurological diseases, among them prevalent placebo effects and unreliable animal models.
At intermission, the gathering hordes convened around Biogen’s limitless coffee supply.
Freshly caffeinated, an attendee (right) does his best superman impression.
Nimbus Therapeutics CEO Don Nicholson (left) and Atlas Venture partner Bruce Booth (right) gave attendees an inside look at a deal that had just been announced two days earlier---Nimbus just sold an experimental drug for nonalcoholic steatohepatitis to Gilead Sciences for as much as $1.2 billion.
Sharp then took the stage with Johnson & Johnson Innovation's Robert Urban to talk Cambridge biotech's past, present, and future---and how "convergence" will be critical going forward.
Make sure to pay attention during these sessions, you’ll have a chance to speak up.
Harvard professor and Warp Drive Bio founder Greg Verdine spoke to a key unmet need in biotech---the fact that current drugmaking methods aren’t good enough to get to a majority of important targets. That’s about to change. “In the next 10 years there will be a revolutionary rewriting of the rules of what we will consider to be a drug-like structure,” he said.
Dartmouth College professor Tillman Gerngross (right) joined with Ironwood Pharmaceuticals CEO Peter Hecht to convene a town hall-style discussion on drug pricing. Gerngross kicked it off talking about some of the advances over the past few decades that the drug industry has been responsible for, and their impact on society.
A number of attendees chimed in on the topic, challenging the panelists.
One, for instance, called on the drug industry to lead a discussion on solutions, rather than point fingers and play the blame game.
After the event, Forum CEO Deborah Dunsire stuck around to meet and greet some attendees.
Also starring in the post-event networking fest was the cheese and fruit platter. Can’t forget that.
What’s hot in Boston biotech? This year, it’s the challenges that lie ahead.
That means drilling down on drug pricing, for one. On Monday, I took a look at that and some of the other insightful nuggets to come out of our event at Biogen. Today, per usual, I’ve come back with visual evidence of the festivities.
One again, a big thanks to our speakers, attendees, event host Biogen, and our supporters: platinum sponsor Ropes & Gray; gold sponsors Fairfax County Economic Development Authority and Pfizer; and silver sponsors ALT Lab Equipment, Mintz Levin, Promega, and The Richmond Group. And thanks to Keith Spiro of Keith Spiro Photography for these photos.
See you all again next year.
Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at firstname.lastname@example.org Follow @benthefidler
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.